Sanofi Q2 Sales Surge 17.8%, Lifts 2026 Outlook; Dupixent Tops €5B/Quarter
SNY is trading near its 52-week low of $40.89 (6.3% above the low).
Summary
Sanofi reported Q2 2026 sales of €11.6 billion (+17.8% at CER) and business EPS of €2.09 (+33.3%), raised 2026 guidance, and set 2030 targets of ~€25B for Dupixent and ~€10B for pharma launches, while discontinuing three pipeline programs.
Updates
· SEC 6-K — H1 2026 net sales were €22,106 million, net income attributable to equity holders €1,957 million, and basic EPS €1.63. The filing includes a €1,031 million impairment of intangible assets, including €952 million for amlitelimab.
Key Events · Earnings and Guidance · SNY
-
Q2 Sales +17.8%, Business EPS +33.3%
Sales reached €11.6 billion, with Dupixent surging 37.6% to €5.2 billion — its first quarter above €5 billion. Pharma launches grew 48.3% to €1.3 billion. Business EPS was €2.09, up 33.3% at constant exchange rates.
-
2026 Guidance Upgraded
Management now expects around 10% sales growth at CER for 2026, with business EPS growing slightly faster than sales, up from prior expectations.
-
2030 Targets Set: Dupixent ~€25B, Launches ~€10B
CEO Belén Garijo provided new long-term targets: Dupixent sales of approximately €25 billion and pharma launches of approximately €10 billion by 2030, both at constant exchange rates.
-
Pipeline Pruning: Three Programs Discontinued
Amlitelimab will not be submitted for atopic dermatitis due to insufficient differentiation; itepekimab (COPD) and balinatunfib (Crohn's/UC) programs were discontinued after disappointing efficacy data.
Analysis · SNY · Life Sciences
A standout quarter saw Sanofi deliver 17.8% constant-currency sales growth, fueled by Dupixent breaking through €5 billion in a single quarter and pharma launches up 48%. Business EPS jumped 33.3%, prompting management to raise full-year guidance — now expecting around 10% sales growth with EPS growing slightly faster. Ambitious 2030 targets were also set: Dupixent at ~€25 billion and pharma launches at ~€10 billion. However, the pipeline saw significant pruning: amlitelimab will not be submitted in atopic dermatitis, and the itepekimab and balinatunfib programs were discontinued, which tempers the long-term growth story. The strong commercial execution and upgraded guidance are clear positives, but the pipeline setbacks and the need for R&D transformation flagged by the new CEO add a note of caution.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNY was trading at $43.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $110.7B. The 52-week trading range was $40.89 to $52.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.